|
|Section2= |Section3= }} Nepicastat (INN, codenamed SYN117, RS-25560-197) is an inhibitor of dopamine beta-hydroxylase, an enzyme that catalyzes the conversion of dopamine to norepinephrine. It has been studied as a possible treatment for congestive heart failure, and appears to be well tolerated as such. As of 2012, clinical trials to assess nepicastat as a treatment for post-traumatic stress disorder (PTSD) and cocaine dependence have been completed.〔 Retrieved on February 1, 2012.〕〔 Retrieved on February 1, 2012.〕 In Phase 2 study treatment with nepicastat was not effective in relieving PTSD-associated symptoms when compared to placebo. The study was funded by the U.S. Department of Defense.〔(Biotie reports top-line data from clinical study with nepicastat (SYN117) in post-traumatic stress disorder ) BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 27 December 2012.〕 ==References== 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Nepicastat」の詳細全文を読む スポンサード リンク
|